Daflon 500

Jump to: navigation, search

DAFLON 500 is also distributed as: Detralex, Arvenum 500, Alvenor, Ardium, Capiven, Elatec and Venitol

DAFLON 500 abridged prescribing information

Presentation and Composition:

Micronized Purified Flavonoid Fraction 500mg: diosmin 450 mg, flavonoids expressed as hesperidin 50 mg.

Therapeutic properties:

Vascular protector and venotonic. DAFLON 500 mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.


Micronization of Daflon 500 mg increases its gastrointestinal absorption compared with nonmicronized diosmin (urinary excretion 57.9% vs 32.7%).

Therapeutic indications:

Treatment of organic and idiopathic chronic venous disease of the lower limbs with the following symptoms: heavy legs, pain, nocturnal cramps, edema. Treatment of hemorrhoids and acute hemorrhoidal attacks.

Side effects:

Some cases of minor gastrointestinal and autonomic disorders have been reported, but these never required cessation of treatment.

Drug interactions:



Pregnancy: experimental studies in animal have not demonstrated any teratogenic effects and no harmful effects have been reported in man to date. Lactation: in the absence of data concerning the diffusion into breast milk, breast-feeding is not recommended during treatment.



Dosage and administration:

In chronic venous disease: 2 tablets daily. In hemorrhoidal disease: - Acute crisis: 6 tablets daily for 4 days, then 4 tablets daily for 3 days. - Chronic treatment: 2 tablets daily.

Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies